Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Incontinence, prolapse & sacral neuromodulation · New York | Incontinence, prolapse & sacral neuromodulation · Pennsylvania | |
|---|---|---|
| Surgeons, 2024 | 38 | 45 |
| Medicare fee-for-service cases | 3,138 | 2,928 |
| Growth since 2019 (Medicare FFS) | −0.8%/yr | +2.4%/yr |
| Forecast cases (Medicare FFS) | 3,860 in 2030 | 3,450 in 2030 |
| Forecast growth | +3.5%/yr to 2030 | +2.8%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 1.7 | 2.1 |
| Medicare Advantage share | 57% | 58% |
| Out of hospital | 8% (+5 pts since 2019) | 8% (+1 pts since 2019) |
| Cases per surgeon | 83 | 65 |
| Top 10 surgeons' share | 48% | 55% |
| Surgeons growing | 7 | 3 |
| New since the base year | 3 | 8 |
| Likely to stop billing it | 7 by 2026 | 15 by 2026 |
| Forecast miss, 1 year (procedure) | 6% | 6% |
| Company payments per surgeon | $19K | $7,703 |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.